Novartis Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Novartis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count).
Novartis Pharmaceuticals: 1,375 sponsored US clinical trials, 110 recruiting.
Novartis Pharmaceuticals sponsors 1,375 registered US clinical trials on ClinicalTrials.gov, 110 of them currently recruiting, and 944 completed. 470 of these trials are in Phase 3-4 (later-stage) and 776 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 10 trials.
Top-decile sponsor footprint
Novartis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
944 of 1,179 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,375 total, page 5 of 28
A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients
NCT07409636
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients
NCT07644351
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
NCT06668324
A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies
NCT07378943
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
NCT07566988
A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors
NCT07512063
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
NCT07477756
A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
NCT07086196
A Study of Real-world Outcomes Among Patients Treated With Ribociclib
NCT07148505
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
NCT07168694
A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients
NCT07151820
Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal
NCT07223476
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
NCT07214857
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
NCT06130540
A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure
NCT07217106
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
NCT07188428
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
NCT06097663
A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
NCT06854341
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
NCT07374120
A Study of the Epidemiology and Hospital Management of Patients With PROS in France
NCT07222423
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
NCT06142383
WOE of Anti-CD20 Therapies
NCT06121349
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
NCT06897657
Effectiveness of Ofatumumab in Real-world Practice
NCT06760624
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
NCT07376265
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
NCT06031844
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
NCT05722522
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
NCT05758415
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
NCT05834738
A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617
NCT07450157
A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia
NCT07415083
A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
NCT05592990
A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
NCT07027163
Safety and Efficacy of RHH646 for Knee Osteoarthritis
NCT05816395
Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
NCT06692803
Long-term Extension Study of Ligelizumab in Food Allergy
NCT05678959
Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
NCT05630001
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
NCT05795153
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
NCT05462873
A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life
NCT06923124
Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
NCT05764265
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
NCT05767034
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
NCT05763875
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
NCT05454410
A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.
NCT05524051
A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
NCT07039383
A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension
NCT06683768
Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
NCT07023445
Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam
NCT05386680
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
NCT05429502
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 326 |
| Phase 2 | 450 |
| Phase 3 | 393 |
| Phase 4 | 77 |
What is open in the Novartis Pharmaceuticals pipeline
110 recruiting of 1,375 indexed (8% open); 944 completed (69%).
Phase mix: 470 late (III/IV) vs 776 early (I/II) (early-phase heavy).
Top condition: Non-Small Cell Lung Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Novartis Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 1,375 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,375 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- Eli Lilly and Company · 1,341 trials · 9% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Arcutis Biotherapeutics · 8% recruiting · 25 trials
- Medtronic Endovascular · 8% recruiting · 25 trials
- Penumbra · 8% recruiting · 25 trials
- SK Life Science · 8% recruiting · 25 trials
Related
What to do with this Novartis Pharmaceuticals page
1,375 registered trials is a research-attention snapshot, not an endorsement of Novartis Pharmaceuticals or any single study.
- 110 of Novartis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Small Cell Lung Cancer is the condition Novartis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Novartis Pharmaceuticals pipeline card: 1,375 registered trials from official public datasets.Report a data error.